Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.64 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.58 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | LSS | P48449 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536182 | 0.96 | VEGFA (0.68) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL2932582 | 0.90 | VEGFA (0.62) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL11932534 | 0.90 | FAAH (0.57) | VEGFAEGLN1MGLLMEN1KMT2A | |
| SCHEMBL2926415 | 0.88 | VEGFA (0.60) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL30834665 | 0.87 | VEGFA (0.56) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL18608789 | 0.85 | MEN1 (0.58) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL2363123 | 0.85 | VEGFA (0.56) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL4938599 | 0.85 | VEGFA (0.56) | VEGFAEGLN1PLA2G7MGLLABHD6 | |
| SCHEMBL2858333 | 0.85 | TP53 (0.58) | VEGFAEGLN1MEN1KMT2AHRH3 | |
| SCHEMBL4156092 | 0.85 | VEGFA (0.58) | VEGFAEGLN1PLA2G7MGLLABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | VEGFA 4206/4885EGLN1 1442/4885PLA2G7 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.